Sunday, May 31, 2026, Chicago, Illinois, 7:00 PM – 9:00 PM Central Time (8:00 PM – 10:00 PM Eastern Time)
What Clinicians Want to Know: Addressing Community Oncologists’ Questions About the Roles of CAR T-Cell Therapy and Bispecific Antibodies in the Management of Non-Hodgkin Lymphoma
A CME Symposium Held Adjunct with the 2026 ASCO® Annual Meeting
Location
Hilton Chicago
720 South Michigan Avenue
Chicago, Illinois
Phone: (312) 922-4400
Program Schedule — Central Time
6:30 PM – 7:00 PM — Registration and Dinner
7:00 PM – 9:00 PM — Educational Meeting
Meeting Room
Continental Room C (Lobby Level)
No registration fee is charged for this event. For the in-person symposium in Chicago, preregistration is required as seating is limited.
Faculty Manali Kamdar, MD, MBBS
Associate Professor
Clinical Director of Lymphoma Services
Morton and Sandra Saffer Endowed Chair in Hematology Research
Division of Hematology, Hematologic Malignancies
University of Colorado Cancer Center
Aurora, Colorado
Jason Westin, MD, MS
Director, Lymphoma Clinical Research
Section Chief, Aggressive Lymphoma
Professor, Department of Lymphoma and Myeloma
The University of Texas MD Anderson Cancer Center
Houston, Texas
Additional faculty to be announced.
Moderator Jeremy S Abramson, MD, MMSc
Director, Center for Lymphoma
Massachusetts General Hospital
Professor of Medicine
Harvard Medical School
Boston, Massachusetts
This activity is supported by educational grants from Bristol Myers Squibb, Genentech, a member of the Roche Group, and Genmab US Inc.
Not an official event of the 2026 ASCO® Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, Association for Clinical Oncology, or Conquer Cancer®, the ASCO Foundation.
Program Schedule — Central Time
6:30 PM – 7:00 PM — Registration and Dinner
7:00 PM – 9:00 PM — Educational Meeting
MODULE 1: Chimeric Antigen Receptor (CAR) T-Cell Therapy for Diffuse Large B-Cell Lymphoma (DLBCL)
Factors such as patient age, performance status, comorbidities or prior therapies influencing eligibility for CAR T-cell therapy
Long-term efficacy and safety data with axicabtagene ciloleucel (axi-cel), tisagenlecleucel (tis-cel) and lisocabtagene maraleucel (liso-cel) for multiregimen-relapsed DLBCL
Major findings from Phase III studies with CAR T-cell therapy as second-line treatment for DLBCL
FDA approvals of axi-cel and liso-cel as second-line therapy, and appropriate identification of candidates for this strategy
Rationale for, preliminary results with and ongoing assessment of CAR T-cell therapy in the up-front setting for high-risk disease
Early results with and ongoing investigation of other CAR T-cell platforms for DLBCL (eg, rapcabtagene autoleucel)
MODULE 2: Bispecific Antibody Therapy for DLBCL
Pharmacologic similarities and differences among the various approved and investigational CD20 x CD3 bispecific antibodies for non-Hodgkin lymphoma (NHL)
Key efficacy and safety outcomes from pivotal studies of glofitamab and epcoritamab monotherapy for relapsed/refractory (R/R) DLBCL
FDA approvals of glofitamab and epcoritamab; evidence-based sequencing of and selection between these agents for R/R DLBCL
Published data with and potential role of odronextamab monotherapy for R/R DLBCL
Available Phase III findings with bispecific antibodies in combination with other anticancer therapies and in earlier settings for DLBCL, including those from STARGLO, SUNMO and Part 1 of the OLYMPIA-3 study
Early data with and ongoing assessment of other bispecific antibody-containing combination strategies for DLBCL
MODULE 3: CAR T-Cell Therapy for Other Lymphoma Subtypes
Extended follow-up with axi-cel, tis-cel and liso-cel for multiregimen-relapsed follicular lymphoma (FL); appropriate selection of candidates with FL for CAR T-cell therapy
Outcomes from the high-risk second-line subgroup of the Phase II TRANSCEND FL study of liso-cel for R/R FL; implications, if any, for therapeutic sequencing
Ongoing and planned trials (eg, ZUMA-22, LEDA, TRANSFORM FL) of CAR T-cell therapy for R/R FL
Key clinical research findings with brexucabtagene autoleucel and liso-cel for R/R mantle cell lymphoma (MCL)
Optimal integration of CAR T-cell therapy into current MCL treatment algorithms
Published results with liso-cel for R/R marginal zone lymphoma (MZL); FDA priority review status and potential clinical role
MODULE 4: Bispecific Antibody Therapy for FL and Other Lymphoma Subtypes
Available data establishing the efficacy and safety of mosunetuzumab and epcoritamab monotherapy for R/R FL
FDA approval of mosunetuzumab and epcoritamab monotherapy for FL after 2 or more lines of systemic therapy; optimal incorporation opposite other available treatment options
Published data with odronextamab monotherapy for R/R FL from the ELM-1 and ELM-2 trials
Ongoing FDA review of odronextamab monotherapy for R/R FL; potential clinical role
Emerging outcomes from the Phase III EPCORE FL-1 study supporting the recent FDA approval of epcoritamab in combination with lenalidomide and rituximab for R/R FL; selection of patients appropriate for this approach
Available research findings with other bispecific antibody-based combination regimens for FL, including in the first-line setting
Available data with, ongoing investigation of and potential clinical role of bispecific antibodies for other NHL subtypes (eg, MCL, MZL)
MODULE 5: Tolerability Considerations with CAR T-Cell Therapy and Bispecific Antibodies
Comparative frequency and severity of cytokine release syndrome (CRS) and neurotoxicity/immune effector cell-associated neurotoxicity syndrome (ICANS) with available anti-CD19 CAR T-cell constructs for various NHL subtypes
Guideline-endorsed approaches for the mitigation, monitoring and management of CRS and neurotoxicity/ICANS; role of corticosteroids, tocilizumab and other supportive care interventions
Rationale for and potential implications of the recent elimination of the Risk Evaluation and Mitigation Strategy for patients receiving CAR T-cell therapy
Long-term tolerability and toxicity considerations (eg, delayed neurotoxicity, cytopenias, hypogammaglobulinemia, infection, secondary malignancy) with CAR T-cell therapy
Incidence, severity and time course of CRS and neurotoxicity/ICANS with bispecific antibody therapy for NHL
Other tolerability concerns with bispecific antibodies for NHL; recommended mitigation and management protocols
Target Audience
This activity is intended for medical oncologists, hematologists, hematology-oncology fellows and other healthcare providers involved in the treatment of lymphoma.
Learning Objectives
Upon completion of this activity, participants should be able to
Develop an understanding of the biological rationale for the development of CD19-directed chimeric antigen receptor (CAR) T-cell therapy as a targeted strategy to eliminate cancer cells in patients with various forms of non-Hodgkin lymphoma (NHL).
Appraise the scientific justification for the evaluation of CD20 x CD3 bispecific antibodies for patients with various forms of NHL, and assess the similarities and differences among currently available agents in this class.
Evaluate the available clinical research database with CD19-directed CAR T-cell therapy and CD20 x CD3 bispecific antibodies in the management of relapsed/refractory diffuse large B-cell lymphoma, and optimally incorporate these approaches into current treatment algorithms.
Assess available research findings with CD19-directed CAR T-cell therapy and CD20 x CD3 bispecific antibodies for other B-cell lymphomas, including follicular lymphoma and mantle cell lymphoma, and identify patients for whom these novel approaches should be considered or recommended.
Recognize adverse events associated with available and investigational CAR T-cell therapies and bispecific antibodies, and implement strategies to educate patients and manage complications.
Recall ongoing research attempting to further define the optimal role of CAR T-cell therapy and bispecific antibody-based strategies for NHL, and counsel patients about potential clinical trial participation.
CME Credit Form
A CME credit link will be given to each participant as part of the meeting course materials.
Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
Research To Practice designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.
Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided.
FACULTY To be announced.
MODERATOR
To be announced.
EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Biotheranostics Inc, A Hologic Company, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Nuvation Bio Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Summit Therapeutics, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.
RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.
Supporters
This activity is supported by educational grants from Bristol Myers Squibb, Genentech, a member of the Roche Group, and Genmab US Inc.
Hilton Chicago
720 South Michigan Avenue
Chicago, IL 60605
Phone: (312) 922-4400
Meeting Room
Continental Room C (Lobby Level)
Directions
The Hilton Chicago hotel is located just 5 minutes (2.5 miles) north of the McCormick Place convention center, where the ASCO Annual Meeting is taking place.
This activity is intended for medical oncologists, hematologists, hematology-oncology fellows and other healthcare providers involved in the treatment of lymphoma.
At this time in-person registration for this educational activity is limited to practicing clinicians actively caring for patients with cancer. For all other professionals, including industry personnel*, we are unable to confirm seating at this time. If you would like to stand by for participation in this event, please provide your contact information by choosing the second registration option below. Should seats become available for the program, we will notify you.
No fee is charged to attend the session virtually.
NOTICE: Registration for this event is independent of registration for the 2026 ASCO Annual Meeting.
IN-PERSON Registration for clinicians in practice/healthcare professionals
I am a practicing physician, fellow, nurse or other healthcare provider involved in the treatment of cancer.
STANDBY IN-PERSON Registration for other/industry professionals*
If you would like to stand by for participation in this event, please provide your contact information here. We will notify you if seats become available.
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk before the start of the meeting. We cannot guarantee seating after the start of the program.
Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.
Research To Practice fully complies with the legal requirements of the ADA. If you require any physical, dietary or other accommodations, please call us at (800) 233-6153 before the event.
Not an official event of the 2026 ASCO® Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, Association for Clinical Oncology, or Conquer Cancer®, the ASCO Foundation.
